newsfilter
← Latest News
GlobeNewswire·

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

  • Immix Biopharma announced its Phase 1/2 interim results for NXC-201 from the NEXICART-2 trial will be presented as an oral presentation at ASH 2025 in Orlando, Florida.
  • The presentation is scheduled for Sunday, December 7, 2025, from 5:45 PM to 6:00 PM ET within the session on MGUS, Amyloidosis, & Other Non-Myeloma Plasma Cell Dyscrasias.
  • The presentation abstract covers safety & efficacy data from the first 20 patients in the first U.S. CAR-T trial for relapsed/refractory light chain amyloidosis.
  • AL amyloidosis is described as a disease where toxic light chains clog organs, with an estimated U.S. patient population of approximately 37,270 in 2025 growing at 12% annually.
  • NXC-201 is a sterically-optimized BCMA-targeted CAR-T cell therapy featuring a "digital filter" to prevent non-specific activation & has received RMAT & Orphan Drug Designations from the FDA & EMA.
  • The NEXICART-2 trial is an ongoing multi-site U.S. Phase 1/2 study with a registrational design expected to enroll 40 patients.
  • Interim results from the NEXICART-2 trial were previously presented at ASCO 2025.
  • The press release includes forward-looking statements regarding trial outcomes, regulatory progress, & capital needs, noting risks that actual results may differ materially from expectations.